Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
2013年11月27日 更新者：Boehringer Ingelheim
A Randomized, Double-blind, Placebo-controlled, 6-week, Crossover Study to Examine the Effects of Tiotropium (Spiriva® HandiHaler®, 18 µg Once Daily) on Dynamic Hyperinflation and Physical Exercise Capacity in Patients With Early Stage Chronic Obstructive Pulmonary Disease (COPD)
Optimal clinical management in early stages of COPD is not established.
Tiotropium has been shown to improve exercise tolerance during (CWR) cycle ergometry with GOLD stage II to IV COPD, improvements in constant speed treadmill time in a study of patients who also received pulmonary rehabilitation in a population of patients with predominantly severe and very severe disease (GOLD stages III and IV) and improvements in exertional dyspnea, and Shuttle Walk Test distance in GOLD stage III and IV COPD.
However, data are lacking on the benefits of tiotropium on exercise tolerance in a patients with early stages of COPD who are symptomatic.
Patients with milder ventilatory limitations (GOLD stages I/II COPD patients) may benefit from maintenance therapy and there is limited data on exercise limitation in patients with early stage COPD who are symptomatic.
This study is designed to evaluate the mechanisms of breathlessness and assess physical activity limitation in early stage COPD patients compared to age and gender matched controls and will secondly investigate the effectiveness of treatment with tiotropium in improving dyspnea during exercise and exercise duration as a result of the bronchodilation effects of tiotropium leading to a reduction of dynamic hyperinflation in Early Stage COPD patients.
研究概览
研究类型
介入性
注册 (实际的)
126
阶段
- 第四阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
Ontario
-
Kingston、Ontario、加拿大
- 205.440.2003 Boehringer Ingelheim Investigational Site
-
-
Quebec
-
Montreal、Quebec、加拿大
- 205.440.2001 Boehringer Ingelheim Investigational Site
-
Montreal、Quebec、加拿大
- 205.440.2004 Boehringer Ingelheim Investigational Site
-
Ste-Foy、Quebec、加拿大
- 205.440.2002 Boehringer Ingelheim Investigational Site
-
-
-
-
Alabama
-
Birmingham、Alabama、美国
- 205.440.1006 Boehringer Ingelheim Investigational Site
-
Jasper、Alabama、美国
- 205.440.1015 Boehringer Ingelheim Investigational Site
-
-
California
-
Torrance、California、美国
- 205.440.1002 Boehringer Ingelheim Investigational Site
-
-
Connecticut
-
Hartford、Connecticut、美国
- 205.440.1018 Boehringer Ingelheim Investigational Site
-
-
Illinois
-
Springfield、Illinois、美国
- 205.440.1008 Boehringer Ingelheim Investigational Site
-
-
Indiana
-
Muncie、Indiana、美国
- 205.440.1017 Boehringer Ingelheim Investigational Site
-
-
Michigan
-
Livonia、Michigan、美国
- 205.440.1020 Boehringer Ingelheim Investigational Site
-
-
New Hampshire
-
Lebanon、New Hampshire、美国
- 205.440.1011 Boehringer Ingelheim Investigational Site
-
-
North Carolina
-
Charlotte、North Carolina、美国
- 205.440.1019 Boehringer Ingelheim Investigational Site
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国
- 205.440.1013 Boehringer Ingelheim Investigational Site
-
-
South Carolina
-
Spartanburg、South Carolina、美国
- 205.440.1007 Boehringer Ingelheim Investigational Site
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
40年 及以上 (成人、年长者)
接受健康志愿者
是的
有资格学习的性别
全部
描述
Inclusion criteria:
For COPD subjects: Male or female, age of 40 years or older, smoking history >10 pack-years, symptomatic defined as baseline dyspnea index focal score of 9 or more and / or daily cough with production of sputum for three months per year during at least two consecutive years, diagnosis of early stage COPD according to: post-bronchodilator FEV1/FVC ratio <70%., FEV1 >/=50% post-bronchodilator predicted normal, and a decreased Inspiratory Capacity during exercise. For Age / Gender Matched Controls: Male or female, age of 40 years or older, nonsmoker, with no significant diseases.
Exclusion criteria:
Patients with a significant disease other than COPD; a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient's ability to participate in the study.
Patients with a history of asthma, Patients requiring the use of supplemental oxygen therapy, Patients who have a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnoea, such as arthritis in the leg, angina pectoris, claudication or other conditions, or Patients with contraindications to exercise.
Note: Additional exclusion criteria for Age / Gender Matched Controls: Patients with a significant disease including COPD.
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：交叉作业
- 屏蔽：双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器：18 mcg tiotropium
Patient to receive 1 tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
|
double blind randomized crossover
|
|
安慰剂比较：Placebo
Patient to receive 1 placebo inhalation powder capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
|
inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
|
|
无干预：Control
Age and gender matched control subjects to conduct incremental and constant work rate exercise tests for comparison to subjects with early stage COPD
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Inspiratory Capacity (IC) at Isotime
大体时间：baseline, six weeks of treatment
|
Inspiratory capacity (IC) during CWR exercise testing measured at isotime (isotime was established during CWR exercise testing at baseline).
Isotime is the minimum exercise time among all tests.
Constant work rate exercise means the exercise is done under constant work rate.
|
baseline, six weeks of treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Constant Work Rate (CWR) Endurance Time
大体时间：six weeks of treatment
|
CWR exercise duration calculated as the length of time of the exercise period
|
six weeks of treatment
|
|
Change From Baseline in Modified Borg Scale Ratings for Dyspnea Intensity at Isotime
大体时间：baseline, six weeks of treatment
|
Modified Borg Scale is a participant rating of the intensity of dyspnea measured on a scale ranging from 0 (Nothing at all) to 10 (Maximal, most severe ever experienced).
|
baseline, six weeks of treatment
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
合作者
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Gagnon P, Casaburi R, Saey D, Porszasz J, Provencher S, Milot J, Bourbeau J, O'Donnell DE, Maltais F. Cluster Analysis in Patients with GOLD 1 Chronic Obstructive Pulmonary Disease. PLoS One. 2015 Apr 23;10(4):e0123626. doi: 10.1371/journal.pone.0123626. eCollection 2015.
- Porszasz J, Blonshine S, Cao R, Paden HA, Casaburi R, Rossiter HB. Biological quality control for cardiopulmonary exercise testing in multicenter clinical trials. BMC Pulm Med. 2016 Jan 16;16:13. doi: 10.1186/s12890-016-0174-8.
- Casaburi R, Maltais F, Porszasz J, Albers F, Deng Q, Iqbal A, Paden HA, O'Donnell DE; 205.440 Investigators. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014 Nov;11(9):1351-61. doi: 10.1513/AnnalsATS.201404-174OC.
- O'Donnell DE, Maltais F, Porszasz J, Webb KA, Albers FC, Deng Q, Iqbal A, Paden HA, Casaburi R; 205.440 investigators. The continuum of physiological impairment during treadmill walking in patients with mild-to-moderate COPD: patient characterization phase of a randomized clinical trial. PLoS One. 2014 May 1;9(5):e96574. doi: 10.1371/journal.pone.0096574. eCollection 2014.
有用的网址
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2010年2月1日
初级完成 (实际的)
2011年11月1日
研究完成 (实际的)
2011年11月1日
研究注册日期
首次提交
2010年2月19日
首先提交符合 QC 标准的
2010年2月19日
首次发布 (估计)
2010年2月22日
研究记录更新
最后更新发布 (估计)
2013年12月24日
上次提交的符合 QC 标准的更新
2013年11月27日
最后验证
2013年4月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.